Tekturna HCT

Tekturna HCT is a brand name of aliskiren/hydrochlorothiazide, approved by the FDA in the following formulation(s):

TEKTURNA HCT (aliskiren hemifumarate; hydrochlorothiazide - tablet; oral)

• 
  Manufacturer: NOVARTIS
  
  Approval date: January 18, 2008
  
  Strength(s): EQ 150MG BASE;12.5MG, EQ 150MG BASE;25MG, EQ 300MG BASE;12.5MG ^[RLD], EQ 300MG BASE;25MG ^[RLD]

Has a generic version of Tekturna HCT been approved?

No. There is currently no therapeutically equivalent version of Tekturna HCT available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tekturna HCT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  .delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides
  Patent 5,559,111
  Issued: September 24, 1996
  Inventor(s): G oschke; Richard & Maibaum; J urgen K. & Schilling; Walter & Stutz; Stefan & Rigollier; Pascal & Yamaguchi; Yasuchika & Cohen; Nissim C. & Herold; Peter
  Assignee(s): Ciba-Geigy Corporation
  .delta.-Amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid amides of formula I ##STR1## and the salts thereof, have renin-inhibiting properties and can be used as antihypertensive medicinal active ingredients.
  
  Patent expiration dates:
  
  
  • July 21, 2018
    
    ✓ 
    Patent use: TREATMENT OF HYPERTENSION
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • January 18, 2011 - NEW COMBINATION
  
  
  • March 5, 2012 - NEW CHEMICAL ENTITY
  
  
  • July 16, 2012 - FOR USE AS INITIAL THERAPY IN PATIENTS WHO ARE LIKELY TO NEED MULTIPLE DRUGS TO ACHIEVE THEIR BLOOD PRESSURE GOALS
  
  

See also...

• Tekturna HCT Consumer Information (Drugs.com)
• Tekturna HCT Consumer Information (Wolters Kluwer)
• Tekturna HCT Consumer Information (Cerner Multum)
• Tekturna HCT Advanced Consumer Information (Micromedex)
• Aliskiren/Hydrochlorothiazide Consumer Information (Wolters Kluwer)
• Hydrochlorothiazide and aliskiren Consumer Information (Cerner Multum)
• Aliskiren and hydrochlorothiazide Advanced Consumer Information (Micromedex)